Remix Therapeutics announced a collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix’s REMaster drug discovery platform. Under the terms of the agreement, Remix will receive an upfront payment of $30M and are eligible to receive up to $12M in near-term milestone payments, as well as preclinical, clinical, commercial and sales milestones of up to $1B and tiered royalties. In exchange, Roche will have exclusive rights to specific targets. Remix will conduct discovery and preclinical activities with Roche, and Roche will be responsible for development and commercialization of any resulting products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RHHBY:
- Roche enters into a definitive agreement to acquire LumiraDx’s Point of Care technology combining multiple diagnostic modalities on a single platform
- FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
- Genentech announces FDA grants Priority Review to sBLA for Xolair
- Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
- Roche completes acquisition of Telavant from Roivant